Newsroom | 33001 results

DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) officially accepted the company’s application for marketing authorization of pimicotinib as a Class 1 innovative drug for adult patients with tenosynovial giant cell tumors (TGCT) requiring systemic treatment. The submission follows the granting of Priority Review to pimicotinib by the CDE in...

DARMSTADT, Germany--(BUSINESS WIRE)--Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) officially accepted the company’s application for marketing authorization of pimicotinib as a Class 1 innovative drug for adult patients with tenosynovial giant cell tumors (TGCT) requiring systemic treatment. The submission follows the granting of Priority Review to p...

EL SEGUNDO, Calif.--(BUSINESS WIRE)--Radiology Partners (RP), the leading technology-enabled radiology practice in the U.S. through its affiliated practices, is proud to announce Chief Medical Officer, Dr. Krishna Nallamshetty, has been recognized by Modern Healthcare as one of 2025’s 50 Most Influential Clinical Executives. A testament to Dr. Nallamshetty’s contributions advancing clinical practices and excellence inside the walls of RP and beyond, this program honors licensed clinicians in ex...

PALO ALTO, Calif.--(BUSINESS WIRE)--Atropos Health, a leader in translating real-world clinical data into personalized real-world evidence (RWE) and insights, and Databricks, the Data and AI company, today announced a partnership to advance precision medicine for healthcare and life sciences organizations. By building on the Databricks Data Intelligence Platform and leveraging Delta Sharing, Atropos Health empowers clinicians and researchers to generate actionable, evidence-based insights to ac...

WALTHAM, Mass.--(BUSINESS WIRE)--BostonGene, a leader in AI-powered solutions for drug discovery and development, today announced that its poster at the 2025 American Society of Clinical Oncology (ASCO) annual meeting has received the GRASP Advocate Choice Award. The poster, titled “Macroscale Genomic Alterations in Histomolecular Invasive Lobular Carcinoma Compared to Other Breast Cancer Subtypes,” was presented by Jason Mouabbi, MD, of The University of Texas MD Anderson Cancer Center, on Jun...

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (Nasdaq: ADTX) (“Aditxt” or the “Company”), a social innovation platform accelerating promising health innovations, today announced the appointment of Saundra Pelletier, CEO of Evofem Biosciences, Inc. (OTCPK: EVFM) (“Evofem”), to Aditxt’s Board of Directors. “We believe that Saundra’s background as a CEO and entrepreneur, coupled with her deep industry expertise and knowledge, will complement our current Board well. We look forward to her co...

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced results from the LIBERATE study published in ESMO Open. The results in the peer-reviewed manuscript demonstrate the clinical validity and high performance of Guardant Reveal, the company’s minimal residual disease (MRD) blood test, in predicting recurrence in patients with early-stage breast cancer. Guardant Reveal uses epigenomic (methylation) analysis to detect circula...

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--DESTINY-Endometrial01 Ph. 3 Trial of ENHERTU Initiated as 1L Therapy in Patients w/ HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer...

RENO, Nev.--(BUSINESS WIRE)--CGT Global supports Renown Health’s new Conrad Breast Center, expanding access to life-changing cancer care in Nevada....

NEWTON, Mass.--(BUSINESS WIRE)--Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, today announced the appointment of Courtney Cupples as Chief Commercial Officer (CCO). Ms. Cupples brings more than 25 years of global commercial leadership and rare disease product launch experience. “We are excited to welcome Courtney to Abcuro as a key member of the leadership team as we...